Canada-based biopharmaceutical company Alpha Cognition has commercially launched Zunveyl (benzgalantamine), a new treatment for mild to moderate Alzheimer’s disease.
Zunveyl is designed to enhance cholinergic function in the brain, thereby improving memory, learning, and overall cognitive function.
The twice-daily treatment aims to provide significant benefits to patients and their caregivers.
Zunveyl offers a differentiated treatment option for patients with mild to moderate Alzheimer’s disease, providing an alternative for those with limited options.
The company is offering Zunveyl in three doses, 5mg, 10mg, and 15mg, through prescriptions filled at pharmacies nationwide.
The commercial launch includes engagement with healthcare providers, payers, and caregivers to support patient access and education.
Alpha Cognition has deployed a nationwide salesforce to engage healthcare providers and ensure Zunveyl reaches those in need.
The commercial strategy targets the long-term care market, the largest segment for Alzheimer’s disease.
Alpha Cognition’s commercial team comprises industry veterans with extensive experience in Alzheimer’s disease and long-term care.
The sales team averages 16 years of industry experience and 10 years in the long-term care market, focusing on rapid adoption and patient access to Zunveyl from the outset.
Alpha Cognition chief operating officer and chief commercial officer Lauren D’Angelo said: “The launch of ZUNVEYL is a game-changer in our fight against Alzheimer’s disease.
“Our team has worked relentlessly to bring this treatment to market, from building out an industry-leading infrastructure to hiring a top-notch sales team, all in record time.
“I’m incredibly proud of the dedication and expertise of our team, and we are excited to partner with healthcare professionals to ensure that patients receive the care they deserve.”
Last year, Alpha Cognition received the US Food and Drug Administration (FDA) approval for Zunveyl (benzgalantamine) to treat mild-to-moderate Alzheimer’s disease.
